Lexaria Bioscience announces partial results from GLP-1-H24-3 study
Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...
Yahoo Finance4d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...
Morningstar5d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Oral delivery of drugs requires far higher quantities of ... its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm, oral DehydraTECH-tirzepatide will be ...
Lexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...
Stockhouse5d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
s leading glucagon-like peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs. Furthermore, the oral DehydraTECH-tirzepatide evidenced a comparable overall reduction in blood glucose from ...
Morningstar4d
Laxxon Medical Announces Positive Pilot PK Study Results (in Pigs) for Groundbreaking Oral GLP-1 Dosage Form
Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to ...